Citations

Clear

4802 citation(s) found for "Yu, Jennifer".

Efficacy of Treatment With Armodafinil for Cancer-Related Fatigue in Patients With High-grade Glioma
Porter, Alyx B. , Liu, Heshan , Kohli, Sadhna , Cerhan, Jane, Sloan, Jeff A. , Loprinzi, Charles L. , Kizilbash, Sani H. , Jaeckle, Kurt A. , Brown, Paul D. , Cerhan, Jane L, McMurray, Ryan P. , Kizilbash, Sani H , Le‐Rademacher, Jennifer , Villano, John L. , Mehta, Minesh P.

Mayo Clinic

JAMA Oncology | December 9, 2021 | Volume: 8 | Issue: 2 | Pages: 259

10.1001/jamaoncol.2021.5948 | PMID 34882169 Get It

Candidacy for Extracorporeal Life Support in Children After Hematopoietic Cell Transplantation: A Position Paper From the Pediatric Acute Lung Injury and Sepsis Investigators Network’s Hematopoietic Cell Transplant and Cancer Immunotherapy Subgroup
Zinter, Matt S. , McArthur, Jennifer , Duncan, Christine , Adams, Roberta H. , Kreml, Erin M., Dalton, Heidi , Abdel‐Azim, Hisham , Rowan, Courtney M. , Gertz, Shira J. , Mahadeo, Kris M. , Randolph, Adrienne G. , Rajapreyar, Prakadeshwari , Steiner, Marie E. , Lehmann, Leslie , Adams, Roberta, Randolph, Adrienne G , Gertz, Shira J

Mayo Clinic

Pediatric Critical Care Medicine | December 8, 2021 | Volume: 23 | Issue: 3 | Pages: 205-213

10.1097/pcc.0000000000002865 | PMID 34878420 Get It

OBJECTIVES: The last decade has seen improved outcomes for children requiring extracorporeal life support as well as for children undergoing hematopoietic cell transplantation. Thus, given the historically poor survival of hematopoietic cell transplantation patients using extracorporeal life support, the Pediatric Acute Lung Injury and Sepsis Investigators’ hematopoietic cell transplantation and cancer immunotherapy subgroup aimed to characterize the utility of extracorporeal life support in facilitating recovery from critical cardiorespiratory illnesses in pediatric hematopoietic cell transplantation patients. DATA SOURCES: All available published data were identified using a set of PubMed search terms for pediatric extracorporeal life support and hematopoietic cell transplantation. STUDY SELECTION: All articles that provided original reports of pediatric hematopoietic cell transplantation patients who underwent extracorporeal life support were included. Sixty-four manuscripts met search criteria. Twenty-four were included as primary reports of pediatric hematopoietic cell transplantation patients who underwent extracorporeal life support (11 were single case reports, four single institution case series, two multi-institution case series, and seven registry reports from Extracorporeal Life Support Organization, Pediatric Heath Information System, and Virtual Pediatric Systems). DATA EXTRACTION: All 24 articles were reviewed by first and last authors and a spread sheet was constructed including sample size, potential biases, and conclusions. DATA SYNTHESIS: Discussions regarding incorporation of available evidence into our clinical practice were held at biannual meetings, as well as through email and virtual meetings. An expert consensus was determined through these discussions and confirmed through a modified Delphi process. CONCLUSIONS: Extracorporeal life support in hematopoietic cell transplantation patients is being used with increasing frequency and potentially improving survival. The Pediatric Acute Lung Injury and Sepsis Investigators hematopoietic cell transplantation-cancer immunotherapy subgroup has developed a framework to guide physicians in decision-making surrounding extracorporeal life support candidacy in pediatric hematopoietic cell transplantation patients. In addition to standard extracorporeal life support considerations, candidacy in the hematopoietic cell transplantation population should consider the following six factors in order of consensus agreement: 1) patient comorbidities; 2) underlying disease necessitating hematopoietic cell transplantation; 3) hematopoietic cell transplantation toxicities, 4) family and patient desires for goals of care; 5) hematopoietic cell transplantation preparatory regimen; and 6) graft characteristics. Although risk assessment may be individualized, data are currently insufficient to clearly delineate ideal candidacy. Therefore, we urge the onco-critical care community to collaborate and capture data to provide better evidence to guide physicians’ decision-making in the future.
Gene-mapping study of extremes of cerebral small vessel disease reveals TRIM47 as a strong candidate
Mishra, Aniket , Duplàa, Cécile , Suzuki, Hideaki , Li, Shuo , Bartz, Traci M. , Jian, Xueqiu , Zhao, Wei , Hofer, Edith , Wittfeld, Katharina , Bis, Joshua C, Adams, Hieab H.H. , Satizábal, Claudia L. , Gottesman, Rebecca F., Gampawar, Piyush , Weiß, Stefan , Yu, Miao , Lopez, Oscar L., Vernooij, Meike W. , Soumaré, Aïcha , Smith, Jennifer A. , Zhu, Yi‐Cheng , Rotter, Jerome I. , Dufouil, Carole , Maniega, Susana Muñoz , Lathrop, Mark, Boerwinkle, Erik, Schmidt, Reinhold, Ihara, Masafumi , Joutel, Anne , Tournier‐Lasserve, Elisabeth , Mosley, Thomas H. , DeCarli, Charles , Tzourio, Christophe , Kardia, Sharon L. R., Teumer, Alexander , Schmidt, Helena , Wardlaw, Joanna M. , Fornage, Myriam , Guðnason, Vilmundur , Longstreth, W.T. , Couffinhal, Thierry , Debette, Stéphanie , Zhao, Wei , Sargurupremraj, Muralidharan , DeCarli, Charles , Suzuki, Hideaki , Sargurupremraj, Muralidharan , Bülow, Robin , Weiss, Stefan , Völker, Uwe , Smith, Jennifer A , Yang, Qiong , Amouyel, Philippe , Tzourio, Christophe , Teumer, Alexander , van Duijn, Cornelia M , Matthews, Paul M , Debette, Stephanie , Wardlaw, Joanna Marguerite , Adams, Hieab H H , Satizabal, Claudia L , Rotter, Jerome I , Vojinović, Dina , Zilhäo, Nuno R. , Harris, Sarah , Auwera, Sandra Van der , Luciano, Michelle , Bis, Joshua C, Bastin, Mark E. , Beiser, Alexa , Völker, Uwe , Kacprowski, Tim , Knopman, David S. , Morris, Zoë , Hernández, Maria del Carmen Valdés , Mazoyer, Bernard , Launer, Lenore J. , Deary, Ian J. , Amouyel, Philippe , Psaty, Bruce M. , Grabe, Hans Jörgen , Duijn, Cornelia M. van , Ikram, M. Arfan , Seshadri, Sudha , Matthews, Paul M.

Mayo Clinic

Brain | December 8, 2021 | Volume: 145 | Issue: 6 | Pages: 1992-2007

10.1093/brain/awab432 | PMID 35511193 Get It

Abstract Cerebral small vessel disease is a leading cause of stroke and a major contributor to cognitive decline and dementia, but our understanding of specific genes underlying the cause of sporadic cerebral small vessel disease is limited. We report a genome-wide association study and a whole-exome association study on a composite extreme phenotype of cerebral small vessel disease derived from its most common MRI features: white matter hyperintensities and lacunes. Seventeen population-based cohorts of older persons with MRI measurements and genome-wide genotyping (n = 41 326), whole-exome sequencing (n = 15 965), or exome chip (n = 5249) data contributed 13 776 and 7079 extreme small vessel disease samples for the genome-wide association study and whole-exome association study, respectively. The genome-wide association study identified significant association of common variants in 11 loci with extreme small vessel disease, of which the chr12q24.11 locus was not previously reported to be associated with any MRI marker of cerebral small vessel disease. The whole-exome association study identified significant associations of extreme small vessel disease with common variants in the 5′ UTR region of EFEMP1 (chr2p16.1) and one probably damaging common missense variant in TRIM47 (chr17q25.1). Mendelian randomization supports the causal association of extensive small vessel disease severity with increased risk of stroke and Alzheimer’s disease. Combined evidence from summary-based Mendelian randomization studies and profiling of human loss-of-function allele carriers showed an inverse relation between TRIM47 expression in the brain and blood vessels and extensive small vessel disease severity. We observed significant enrichment of Trim47 in isolated brain vessel preparations compared to total brain fraction in mice, in line with the literature showing Trim47 enrichment in brain endothelial cells at single cell level. Functional evaluation of TRIM47 by small interfering RNAs-mediated knockdown in human brain endothelial cells showed increased endothelial permeability, an important hallmark of cerebral small vessel disease pathology. Overall, our comprehensive gene-mapping study and preliminary functional evaluation suggests a putative role of TRIM47 in the pathophysiology of cerebral small vessel disease, making it an important candidate for extensive in vivo explorations and future translational work.
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Gnant, Michael , Dueck, Amylou C. , Frantal, Sophie, Martín, Miguel , Burstein, H.J., Greil, Richard , Fox, Peter , Wolff, Antonio C. , Chan, Arlene , Winer, Eric P. , Pfeiler, Georg , Miller, Kathy D. , Suga, Jennifer M. , Rubovsky, Gabor, Bliss, Judith M. , Nowecki, Zbigniew , Hahn, Olwen, Thomson, Jacqui, Amillano, Kepa , Rugo, Hope S. , Steger, Guenther G. , Aranguiz, Blanca Hernando Fernández de , Haddad, Tufia C. , Perelló, Antonia , Bellet, Meritxell , Fohler, Hannes, Jallitsch-Halper, Anita, Solomon, Kadine, Schurmans, Céline , Theall, K. P., Lu, Dongrui R. , Tenner, Kathleen , Fesl, Christian , investigators, on behalf of the PALLAS groups and, Colleoni, Marco , Rubovsky, Gabor , Mayer, IA , Singer, Christian F , Nowecki, Zbigniew , Thomson, Jacqui , Rugo, Hope S , Hernando Fernández de Aránguiz, Blanca , Haddad, Tufia C , Metzger Filho, Otto , Schurmans, Céline , Lu, Dongrui R , Fesl, Christian , DeMichele, Angela , Mayer, Erica L , Dueck, A. C. , Wolff, Antonio C , Winer, Eric , Martin, Miguel , Gnant, Michael , Miller, Kathy D , Bliss, Judith , Colleoni, Marco , Mayer, Ingrid A. , Singer, Christian F. , Wolmark, Norman , Metzger, Otto , DeMichele, Angela , Mayer, Erica L. , investigators, on behalf of the PALLAS groups and

Mayo Clinic

Journal of Clinical Oncology | December 7, 2021 | Volume: 40 | Issue: 3 | Pages: 282-293

10.1200/jco.21.02554 | PMID 34874182 Get It

PURPOSE Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, the potential value of adding palbociclib to endocrine therapy for hormone receptor–positive breast cancer has not been confirmed. PATIENTS AND METHODS In the prospective, randomized, phase III PALLAS trial, patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative early breast cancer were randomly assigned to receive 2 years of palbociclib (125 mg orally once daily, days 1-21 of a 28-day cycle) with adjuvant endocrine therapy or adjuvant endocrine therapy alone (for at least 5 years). The primary end point of the study was invasive disease-free survival (iDFS); secondary end points were invasive breast cancer–free survival, distant recurrence-free survival, locoregional cancer-free survival, and overall survival. RESULTS Among 5,796 patients enrolled at 406 centers in 21 countries worldwide over 3 years, 5,761 were included in the intention-to-treat population. At the final protocol-defined analysis, at a median follow-up of 31 months, iDFS events occurred in 253 of 2,884 (8.8%) patients who received palbociclib plus endocrine therapy and in 263 of 2,877 (9.1%) patients who received endocrine therapy alone, with similar results between the two treatment groups (iDFS at 4 years: 84.2% v 84.5%; hazard ratio, 0.96; CI, 0.81 to 1.14; P = .65). No significant differences were observed for secondary time-to-event end points, and subgroup analyses did not show any differences by subgroup. There were no new safety signals for palbociclib in this trial. CONCLUSION At this final analysis of the PALLAS trial, the addition of adjuvant palbociclib to standard endocrine therapy did not improve outcomes over endocrine therapy alone in patients with early hormone receptor–positive breast cancer.
COVID-19 Care Clinic in a Medical Center: Lessons Learned
Tulledge‐Scheitel, Sidna M. , Billings, Thomas A., Homme, Jason H. , Miller, Jennifer , North, Frederick , Sanderson, Rachael L. , Schroeder, Darrell R. , Vaughan, Marvin A., Croghan, Ivana T. , Miller, Jennifer M, Sanderson, Rachael L , Croghan, Ivana T , Schroeder, Darrell , Billings, Thomas A., Fischer, Karen M.

Mayo Clinic

Journal of Primary Care & Community Health | December 7, 2021 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/21501327211056796 | PMID 34872410 Get It

Objective: The purpose of this report is to describe the elements of a Covid-19 Care Clinic (CCC), patient demographics, and outcomes. Methods: Descriptive statistics were used to describe demographics, clinical characteristics, and outcomes. This report is based on 4934 unique patients seen in the CCC who provided research authorization within a 10-month period of time (April 1, 2020-January 31, 2021). The CCC infection control processes consisted of a rooming process that mitigated SARS-COV-2 transmission, preparing examination rooms, using PPE by staff, in room lab drawing, and escorting services to minimize the time in clinic. Results: Of the 4934 unique patients seen (age range newborn-102 years), 76.8% were tested for COVID-19. Of those tested, 11.8% were positive for SARS-CoV-2. Ninety-two percent of the patients with the reason for the visit documented had COVID-19 type symptoms. Cough, shortness of breath, and chest pain were the most common presenting symptom in those with COVID-19. At the time of the visit in the CCC, 5.8% of the patients were actively contagious. Thirty days after being seen in the CCC, 9.1% of the patients were seen in the emergency department (ED) and 0.2% died. During the 10-month period there were no known occupationally related COVID-19 infections. Conclusion: The COVID-19 Care Clinic provided face-to-face access for all ages with COVID-19 type symptoms. A minority of patients had COVID-19 who were seen in the clinic. The clinic provided an additional venue of care outside of the ED. The infectious control measures employed were highly effective in protecting the staff. Lessons learned allow for decentralization of COVID-19 symptom care to the primary care practices employing the infection control measures.
Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID
Weaver, Kimberly N. , Zhang, Xian , Dai, Xiangfeng , Watkins, Runa , Adler, Jeremy, Dubinsky, Marla C. , Kastl, Arthur , Bousvaros, Athos, Strople, Jennifer , Cross, Raymond K. , Higgins, Peter , Bewtra, Meenakshi , Bellaguarda, Emanuelle, Boccieri, Margie , Firestine, Ann M. , Long, Millie D. , Cross, Raymond , Adler, Jeremy, Ungaro, Ryan C. , Farraye, Francis A. , Kappelman, Michael D. , Adler, J

Mayo Clinic

Inflammatory Bowel Diseases | December 6, 2021 | Volume: 28 | Issue: 10 | Pages: 1497-1505

10.1093/ibd/izab302 | PMID 34871388 Get It

Abstract Background Severe acute respiratory syndrome coronavirus 2 vaccination is recommended for all individuals with inflammatory bowel disease (IBD), including those on immunosuppressive therapies; however, little is known about vaccine safety and efficacy in these patients or the impact of vaccination on IBD disease course. Methods We evaluated coronavirus disease 2019 (COVID-19) vaccine–related adverse events (AEs) and the effect of vaccination on IBD disease course among participants in the PREVENT-COVID (Partnership to Report Effectiveness of Vaccination in populations Excluded from iNitial Trials of COVID) study, a prospective, observational cohort study. Localized and systemic reactions were assessed via questionnaire. Disease flare was defined by worsening IBD symptoms and change in IBD medications. Outcomes were stratified by vaccine type and IBD medication classes. Results A total of 3316 individuals with IBD received at least 1 COVID-19 vaccine. Injection site tenderness (68%) and fatigue (46% dose 1, 68% dose 2) were the most commonly reported localized and systemic AEs after vaccination. Severe localized and systemic vaccine-related AEs were rare. The mRNA-1273 vaccine was associated with significantly greater severe AEs at dose 2 (localized 4% vs 2%, systemic 15% vs 10%; P < .001 for both). Prior COVID-19 infection, female sex, and vaccine type were associated with severe systemic reactions to dose 1, while age <50 years, female sex, vaccine type, and antitumor necrosis factor and vedolizumab use were associated with severe systemic reactions to dose 2. Overall rates (2%) of IBD flare were low following vaccination. Conclusions Our findings provide reassurance that the severe acute respiratory syndrome coronavirus 2 vaccine is safe and well tolerated among individuals with IBD, which may help to combat vaccine hesitancy and increase vaccine confidence.
Shared Decision Making in Cardiac Electrophysiology Procedures and Arrhythmia Management
Chung, Mina K. , Fagerlin, Angela , Wang, Paul J. , Ajayi, Tinuola B. , Allen, Larry A. , Baykaner, Tina , Benjamin, Emelia J. , Branda, Megan E. , Cavanaugh, Kerri L. , Delaney, Rebecca K. , Eckhardt, Lee L. , Hargraves, Ian , Hills, Mellanie True , Kalscheur, Matthew M. , Kramer, Daniel B. , Kunneman, Marleen , Lampert, Rachel , Lewis, Krystina B. , Lü, Ying , Matlock, Daniel D. , McCarthy, Sarah , Orland, Kate M. , Pundi, Krishna , Roden, Dan M. , Saarel, Elizabeth V. , Schmidt, Monika M. , Sears, Samuel F. , Stafford, Randall S. , Wass, Sojin Y. , Wright, Jennifer M. , McCarthy, Sarah R. , Branda, Megan , Chen, Lin Y , Delaney, Rebecca K , Eckhardt, Lee L , Grady, Kathleen L , Hargraves, Ian G, True Hills, Mellanie , Kalscheur, Matthew M , Kramer, Daniel B , Kunneman, Marleen , Lampert, Rachel , Langford, Aisha T , Lewis, Krystina B , Lu, Ying , Mandrola, John M , Martinez, Kathryn , Matlock, Daniel D , McCarthy, Sarah R , Montori, Victor M , Noseworthy, Peter A , Orland, Kate M , Ozanne, Elissa M , Passman, Rod , Pundi, Krishna , Roden, Dan M. , Saarel, Elizabeth V , Schmidt, Monika M , Sears, Samuel F , Stacey, Dawn , Stafford, Randall S , Steinberg, Benjamin A , Youn Wass, Sojin , Wright, Jennifer M , Cavanaugh, Kerri , Benjamin, Emelia J , Fagerlin, Angela , Chen, Lin Y. , Crossley, George , Martinez, Kathryn A. , Montori, Víctor M. , Noseworthy, Peter A. , Ozanne, Elissa M. , Passman, Rod , Stacey, Dawn , Steinberg, Benjamin A. , McCarthy, Sarah R.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | December 6, 2021 | Volume: 14 | Issue: 12 | Pages: No page available

10.1161/circep.121.007958 | PMID 34865518 Get It

Shared decision making (SDM) has been advocated to improve patient care, patient decision acceptance, patient-provider communication, patient motivation, adherence, and patient reported outcomes. Documentation of SDM is endorsed in several society guidelines and is a condition of reimbursement for selected cardiovascular and cardiac arrhythmia procedures. However, many clinicians argue that SDM already occurs with clinical encounter discussions or the process of obtaining informed consent and note the additional imposed workload of using and documenting decision aids without validated tools or evidence that they improve clinical outcomes. In reality, SDM is a process and can be done without decision tools, although the process may be variable. Also, SDM advocates counter that the low-risk process of SDM need not be held to the high bar of demonstrating clinical benefit and that increasing the quality of decision making should be sufficient. Our review leverages a multidisciplinary group of experts in cardiology, cardiac electrophysiology, epidemiology, and SDM, as well as a patient advocate. Our goal is to examine and assess SDM methodology, tools, and available evidence on outcomes in patients with heart rhythm disorders to help determine the value of SDM, assess its possible impact on electrophysiological procedures and cardiac arrhythmia management, better inform regulatory requirements, and identify gaps in knowledge and future needs.
The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer
Larson, Samantha, Boudreau, Jenna, Bulin, Jennifer, Rolf, Mallory, Hanna, Kirollos S. , Nguyen, Jenny

Mayo Clinic

American Journal of Health-System Pharmacy | December 5, 2021 | Volume: 79 | Issue: 8 | Pages: 629-635

10.1093/ajhp/zxab464 | PMID 34864835 Get It

Abstract Purpose The treatment landscape of advanced bladder cancer continues to evolve with novel therapeutics approved in recent years and many in the pipeline. Here we review the role of the novel agents enfortumab vedotin and sacituzumab govitecan in treatment of advanced disease. Summary Patients with advanced bladder cancer often first receive platinum-based therapy, while immune checkpoint inhibitors offer a maintenance option following cytotoxic chemotherapy or a second-line option. Despite various first- and second-line options, patients with significant comorbidities and treatment-related adverse events will experience disease progression requiring alternative treatment. Enfortumab vedotin and sacituzumab govitecan are novel antibody-drug conjugates approved in patients with advanced bladder cancer following platinum-based and immune checkpoint inhibitor therapy. Following platinum-based therapy and immunotherapy in patients with advanced bladder cancer, enfortumab vedotin, targeting Nectin-4, improves overall survival while sacituzumab govitecan, targeting Trop-2, is associated with a 27% response rate. With these new approaches to disease management, however, it remains critical to understand safety, efficacy, and operational considerations to optimize outcomes. Conclusion When selecting an antibody-drug conjugate to treat patients with bladder cancer, it is important to note the adverse event profile of each agent to optimize outcomes and safety for patients.
Investigating the Immunopathogenic Mechanisms Underlying MOGAD
McCombe, Jennifer A. , Chen, John J. , Ζεκερίδου, Αναστασία , Lucchinetti, Claudia F. , Pittock, Sean J. , Zekeridou, Anastasia , Pittock, S J , Chen, John J , Flanagan, Eoin P.

Mayo Clinic

Annals of Neurology | December 4, 2021 | Volume: 91 | Issue: 2 | Pages: 299-300

10.1002/ana.26279 | PMID 34862992 Get It

Socioeconomic and demographic factors in the diagnosis and treatment of Chiari malformation type I and syringomyelia
Akbari, Syed Hassan A., Rizvi, Asad A., CreveCoeur, Travis S., Han, Rowland H., Greenberg, Jacob K., Torner, James, Brockmeyer, Douglas L., Wellons, John C., Leonard, Jeffrey R., Mangano, Francesco T., Johnston, James M., Shah, Manish N., Iskandar, Bermans J., Ahmed, Raheel, Tuite, Gerald F., Kaufman, Bruce A., Daniels, David J., Jackson, Eric M., Grant, Gerald A., Powers, Alexander K., Couture, Daniel E., Adelson, P. David, Alden, Tord D., Aldana, Philipp R., Anderson, Richard C. E., Selden, Nathan R., Bierbrauer, Karin, Boydston, William, Chern, Joshua J., Whitehead, William E., Dauser, Robert C., Ellenbogen, Richard G., Ojemann, Jeffrey G., Fuchs, Herbert E., Guillaume, Daniel J., Hankinson, Todd C., O’Neill, Brent R., Iantosca, Mark, Oakes, W. Jerry, Keating, Robert F., Klimo, Paul, Muhlbauer, Michael S., McComb, J. Gordon, Menezes, Arnold H., Khan, Nickalus R., Niazi, Toba N., Ragheb, John, Shannon, Chevis N., Smith, Jodi L., Ackerman, Laurie L., Jea, Andrew H., Maher, Cormac O., Narayan, Prithvi, Albert, Gregory W., Stone, Scellig S. D., Baird, Lissa C., Gross, Naina L., Durham, Susan R., Greene, Stephanie, McKinstry, Robert C., Shimony, Joshua S., Strahle, Jennifer M., Smyth, Matthew D., Dacey, Ralph G., Park, Tae Sung, Limbrick, David D., Torner, James C. , Greene, Stephanie , Jackson, Eric M. , Stone, Scellig , Akbari, Syed Hassan A., Rizvi, Asad A., CreveCoeur, Travis S., Han, Rowland H., Greenberg, Jacob K., Brockmeyer, Douglas L., Wellons, John C., Leonard, Jeffrey R., Mangano, Francesco T., Johnston, James M., Shah, Manish N., Iskandar, Bermans J., Ahmed, Raheel, Tuite, Gerald F., Kaufman, Bruce A., Daniels, David J., Jackson, Eric M., Grant, Gerald A., Powers, Alexander K., Couture, Daniel E., Adelson, P. David, Alden, Tord D., Aldana, Philipp R., Anderson, Richard C. E., Selden, Nathan R., Bierbrauer, Karin, Boydston, William, Chern, Joshua J., Whitehead, William E., Dauser, Robert C., Ellenbogen, Richard G., Ojemann, Jeffrey G., Fuchs, Herbert E., Guillaume, Daniel J., Hankinson, Todd C., O’Neill, Brent R., Iantosca, Mark, Oakes, W. Jerry, Keating, Robert F., Klimo, Paul, Muhlbauer, Michael S., McComb, J. Gordon, Menezes, Arnold H., Khan, Nickalus R., Niazi, Toba N., Ragheb, John, Shannon, Chevis N., Smith, Jodi L., Ackerman, Laurie L., Jea, Andrew H., Maher, Cormac O., Narayan, Prithvi, Albert, Gregory W., Stone, Scellig S. D., Baird, Lissa C., Gross, Naina L., Durham, Susan R., Greene, Stephanie, McKinstry, Robert C., Shimony, Joshua S., Strahle, Jennifer M., Smyth, Matthew D., Dacey, Ralph G., Park, Tae Sung, Limbrick, David D.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | December 3, 2021 | Volume: 29 | Issue: 3 | Pages: 288-297

10.3171/2021.9.peds2185 | PMID 34861643 Get It

OBJECTIVE The goal of this study was to assess the social determinants that influence access and outcomes for pediatric neurosurgical care for patients with Chiari malformation type I (CM-I) and syringomyelia (SM). METHODS The authors used retro- and prospective components of the Park-Reeves Syringomyelia Research Consortium database to identify pediatric patients with CM-I and SM who received surgical treatment and had at least 1 year of follow-up data. Race, ethnicity, and insurance status were used as comparators for preoperative, treatment, and postoperative characteristics and outcomes. RESULTS A total of 637 patients met inclusion criteria, and race or ethnicity data were available for 603 (94.7%) patients. A total of 463 (76.8%) were non-Hispanic White (NHW) and 140 (23.2%) were non-White. The non-White patients were older at diagnosis (p = 0.002) and were more likely to have an individualized education plan (p < 0.01). More non-White than NHW patients presented with cerebellar and cranial nerve deficits (i.e., gait ataxia [p = 0.028], nystagmus [p = 0.002], dysconjugate gaze [p = 0.03], hearing loss [p = 0.003], gait instability [p = 0.003], tremor [p = 0.021], or dysmetria [p < 0.001]). Non-White patients had higher rates of skull malformation (p = 0.004), platybasia (p = 0.002), and basilar invagination (p = 0.036). Non-White patients were more likely to be treated at low-volume centers than at high-volume centers (38.7% vs 15.2%; p < 0.01). Non-White patients were older at the time of surgery (p = 0.001) and had longer operative times (p < 0.001), higher estimated blood loss (p < 0.001), and a longer hospital stay (p = 0.04). There were no major group differences in terms of treatments performed or complications. The majority of subjects used private insurance (440, 71.5%), whereas 175 (28.5%) were using Medicaid or self-pay. Private insurance was used in 42.2% of non-White patients compared to 79.8% of NHW patients (p < 0.01). There were no major differences in presentation, treatment, or outcome between insurance groups. In multivariate modeling, non-White patients were more likely to present at an older age after controlling for sex and insurance status (p < 0.01). Non-White and male patients had a longer duration of symptoms before reaching diagnosis (p = 0.033 and 0.004, respectively). CONCLUSIONS Socioeconomic and demographic factors appear to influence the presentation and management of patients with CM-I and SM. Race is associated with age and timing of diagnosis as well as operating room time, estimated blood loss, and length of hospital stay. This exploration of socioeconomic and demographic barriers to care will be useful in understanding how to improve access to pediatric neurosurgical care for patients with CM-I and SM.